Compare IDEXX Laboratories, Inc. (IDXX) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Transocean Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $571.3 (market cap $46.22B), while Transocean Ltd trades at $5.71 (market cap $6.49B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.1× Transocean Ltd's market cap, and Transocean Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | RIG | |
|---|---|---|
Market Cap | $46.22B | $6.49B |
Sector | Health | Technology |
52-Week High | $766.68 | $7.58 |
52-Week Low | $526.44 | $2.80 |
Enterprise Value | $47.12B | $11.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Transocean Ltd. (RIG) trades at $5.68, down 0.7% on the day. The stock shows a bullish technical signal with strong moving average support, though the RSI suggests mild overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat but continues to post net losses, with a negative net income margin of -40.24%. Revenue remains stable near $4.1 billion, and the pending Valaris merger offers growth potential. Analyst sentiment is mixed but leans positive, with 39% recommending buy.
The outlook for RIG hinges on operational improvements and merger synergies, but persistent losses and high debt pose significant risks. Investors should weigh the potential upside from contract wins and fleet utilization against the company's current unprofitability and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
